Long-term Outcomes of Boston Type 1 Keratoprosthesis Implantation: a Retrospective Multicenter Cohort
Overview
Authors
Affiliations
Purpose: To study the long-term outcomes of Boston type 1 keratoprosthesis (KPro) surgery.
Design: Retrospective, multicenter case series.
Participants: A total of 158 eyes of 150 patients underwent KPro implantation at 5 participating tertiary centers in the United States between January 2003 and December 2006. Of those, 139 eyes of 133 patients were included in the analyses.
Methods: The medical records of consecutive adult patients who received KPro surgery were reviewed. All patients with at least 1 postoperative visit were retained in the outcomes analyses. In eyes in which a repeat KPro procedure was performed, only the outcomes of the initial surgery were analyzed.
Main Outcome Measures: Visual acuity (VA) outcomes, postoperative complications, and device retention.
Results: The mean follow-up was 46.7 ± 26 months with all but 4 eyes having at least 6 months of follow-up. Preoperatively, only 10.8% of the eyes had VA of ≥ 20/200. Postoperatively, the VA in 70% of eyes improved to ≥ 20/200. The probability of maintaining VA of ≥ 20/200 at 7 years was 50%. The device retention rate was estimated at 67% at 7 years. The 7-year cumulative incidence of complications was 49.7% for retroprosthetic membrane formation, 21.6% for glaucoma surgery, 18.6% for retinal detachment, and 15.5% for endophthalmitis.
Conclusions: Although the risk for complications with longer follow-up seemed to increase, this large multicenter cohort demonstrates favorable outcomes with KPro, with a large number of patients achieving and retaining useful vision over a 7-year period.
Two cases of therapeutic scleral lenses for KID syndrome.
Gagliardi M, Asghari B Am J Ophthalmol Case Rep. 2025; 37:102261.
PMID: 39927073 PMC: 11804770. DOI: 10.1016/j.ajoc.2025.102261.
Biomedical Application of MSCs in Corneal Regeneration and Repair.
De Miguel M, Cadenas-Martin M, Stokking M, Martin-Gonzalez A Int J Mol Sci. 2025; 26(2).
PMID: 39859409 PMC: 11766311. DOI: 10.3390/ijms26020695.
Wroblewska-Czajka E, Dobrowolski D, Wylegala A, Jurkunas U, Wylegala E J Clin Med. 2024; 13(4).
PMID: 38398288 PMC: 10889181. DOI: 10.3390/jcm13040975.
An artificially-intelligent cornea with tactile sensation enables sensory expansion and interaction.
Qu S, Sun L, Zhang S, Liu J, Li Y, Liu J Nat Commun. 2023; 14(1):7181.
PMID: 37935671 PMC: 10630301. DOI: 10.1038/s41467-023-42240-3.
Application of biomaterials and nanotechnology in corneal tissue engineering.
Soleimani M, Ebrahimi Z, Ebrahimi K, Farhadian N, Shahlaei M, Cheraqpour K J Int Med Res. 2023; 51(7):3000605231190473.
PMID: 37523589 PMC: 10392709. DOI: 10.1177/03000605231190473.